Pfizer Inc. $PFE Stock Position Lifted by Park National Corp OH

Key Points

• Park National Corp OH increased its Pfizer stake by 332.1% in the second quarter, holding 242,081 shares worth approximately $5.8 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, beating estimates of $0.68, while revenue reached $15.03 billion, up 2.6% year over year. The company also declared a quarterly dividend of $0.43, representing a 6.4% annualized yield.
• Despite positive developments such as progress on a Lyme disease vaccine, analysts maintain a consensus “Hold” rating with a $28.28 price target, citing post-COVID revenue declines, asset impairments and pipeline execution risks.

Park National Corp OH raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 332.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 242,081 shares of the biopharmaceutical company's stock after buying an additional 186,053 shares during the period. Park National Corp OH's holdings in Pfizer were worth $5,829,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. State Street Corp grew its stake in Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock valued at $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC grew its stake in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley increased its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Norges Bank acquired a new position in Pfizer in the 4th quarter worth about $1,830,986,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE opened at $26.77 on Friday. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The stock's 50-day moving average is $25.12 and its two-hundred day moving average is $26.20. The firm has a market cap of $152.60 billion, a P/E ratio of 35.23 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's payout ratio is 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source